Literature DB >> 31231436

Perspectives for Concepts of Individualized Radionuclide Therapy, Molecular Radiotherapy, and Theranostic Approaches.

Makoto Hosono1.   

Abstract

Radionuclide therapy (RNT) stands on the delivery of radiation to tumors or non-tumor target organs using radiopharmaceuticals that are designed to have specific affinity to targets. RNT is recently called molecular radiotherapy (MRT) by some advocators in order to emphasize its characteristics as radiotherapy and the relevance of dosimetry-guided optimization of treatment. Moreover, RNT requires relevant radiation protection standards because it employs unsealed radionuclides and gives therapeutic radiation doses in humans. On the basis of these radiation protection standards, the development and use of radiopharmaceuticals for combined application through diagnostics and therapeutics lead to theranostic approaches that will enhance the efficacy and safety of treatment by implementing dosimetry-based individualization.

Entities:  

Keywords:  Radionuclide therapy; Radiopharmaceuticals; Theranostics

Year:  2019        PMID: 31231436      PMCID: PMC6554368          DOI: 10.1007/s13139-019-00586-x

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  47 in total

1.  The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103.

Authors: 
Journal:  Ann ICRP       Date:  2007

2.  Bexxar, iodine I 131 tositumomab, effective in long-term follow-up of non-Hodgkin's lymphoma.

Authors:  Mark Kaminski
Journal:  Cancer Biol Ther       Date:  2007-07       Impact factor: 4.742

3.  Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.

Authors:  Gregory A Wiseman; Ellen Kornmehl; Bryan Leigh; William D Erwin; Donald A Podoloff; Stewart Spies; Richard B Sparks; Michael G Stabin; Thomas Witzig; Christine A White
Journal:  J Nucl Med       Date:  2003-03       Impact factor: 10.057

4.  Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.

Authors:  Thomas E Witzig; Arturo Molina; Leo I Gordon; Christos Emmanouilides; Russell J Schilder; Ian W Flinn; Mohamed Darif; Roger Macklis; Katie Vo; Gregory A Wiseman
Journal:  Cancer       Date:  2007-05-01       Impact factor: 6.860

Review 5.  Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.

Authors:  Henry N Wagner; Gregory A Wiseman; Carol S Marcus; Hani A Nabi; Conrad E Nagle; Darlene M Fink-Bennett; Dominick M Lamonica; Peter S Conti
Journal:  J Nucl Med       Date:  2002-02       Impact factor: 10.057

Review 6.  Radionuclide therapy.

Authors:  J F Chatal; C A Hoefnagel
Journal:  Lancet       Date:  1999-09-11       Impact factor: 79.321

7.  ICRP Publication 105. Radiation protection in medicine.

Authors: 
Journal:  Ann ICRP       Date:  2007

8.  Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

Authors:  Lisa Bodei; Marta Cremonesi; Mahila Ferrari; Monica Pacifici; Chiara M Grana; Mirco Bartolomei; Silvia M Baio; Maddalena Sansovini; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-22       Impact factor: 9.236

9.  90Y-ibritumomab therapy in refractory non-Hodgkin's lymphoma: observations from 111In-ibritumomab pretreatment imaging.

Authors:  Andrei Iagaru; Sanjiv Sam Gambhir; Michael L Goris
Journal:  J Nucl Med       Date:  2008-10-16       Impact factor: 10.057

Review 10.  Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".

Authors:  B Brans; L Bodei; F Giammarile; O Linden; M Luster; W J G Oyen; J Tennvall
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05       Impact factor: 9.236

View more
  1 in total

Review 1.  Radiolabeled nanomaterials for biomedical applications: radiopharmacy in the era of nanotechnology.

Authors:  Martha Sahylí Ortega Pijeira; Herlys Viltres; Jan Kozempel; Michal Sakmár; Martin Vlk; Derya İlem-Özdemir; Meliha Ekinci; Seshasai Srinivasan; Amin Reza Rajabzadeh; Eduardo Ricci-Junior; Luciana Magalhães Rebelo Alencar; Mohammed Al Qahtani; Ralph Santos-Oliveira
Journal:  EJNMMI Radiopharm Chem       Date:  2022-04-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.